Carcinoma in situ of skin of unspecified lower limb, including hip
ICD-10 D04.70 is a billable code used to indicate a diagnosis of carcinoma in situ of skin of unspecified lower limb, including hip.
Carcinoma in situ (CIS) of the skin represents a localized form of skin cancer where abnormal cells are present but have not invaded deeper tissues. This specific code, D04.70, pertains to CIS located in the skin of the lower limb, including the hip, but does not specify the exact site. CIS is characterized by the presence of atypical keratinocytes confined to the epidermis, and it is considered a precursor to invasive squamous cell carcinoma. Patients with CIS may present with various skin lesions, including scaly patches, non-healing sores, or changes in existing moles. Surveillance protocols typically involve regular dermatological examinations to monitor for any changes in the lesions, as well as patient education on sun protection and skin self-examinations. The risk of progression to invasive cancer varies, with factors such as lesion size, duration, and patient history influencing the likelihood of progression. Early detection and treatment are crucial to prevent the development of invasive carcinoma.
Detailed descriptions of lesions, treatment plans, and follow-up care.
Diagnosis and management of skin lesions, including biopsies and excisions.
Ensure accurate documentation of lesion size, location, and histological findings.
Comprehensive treatment plans, including surgical and non-surgical interventions.
Management of patients with skin cancers and monitoring for progression.
Documenting patient history and risk factors for skin cancer.
Used when a biopsy is performed to confirm CIS diagnosis.
Document the site, size, and characteristics of the lesion.
Dermatologists should ensure thorough documentation of the procedure.
Carcinoma in situ is a localized form of cancer where abnormal cells are present but have not invaded surrounding tissues. It is often considered a precursor to invasive cancer.
